Pfizer
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday. Innovent, which is based in Suzhou in China’s eastern Jiangsu...
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.
Which company could become the Chinese Pfizer? Here are analysts’ top picks
Which company could become the Chinese Pfizer? Here are analysts’ top picks A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands A handful of Chinese biotechnology companies are expected to bring medications to consumers in Europe and the US under their own brand names within the next 10 to 15 years, according to policy and industry analysts. Outlicensing agreements typically refer to a company granting...
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It may be fewer injections. Pfizer and Amgen are developing monthly GLP-1 shots — a departure from injections like Wegovy and Zepbound, which are taken weekly.
Accenture CEO Julie Sweet on one of the most-important lessons her dad taught her
Accenture CEO Julie Sweet has credited a conversation with her father during her teenage years as one of the defining moments of her life and career. She shared how a lesson about merit, preparation, and self-belief shaped her outlook on success. Speaking during a recent one-on-one conversation with Pfizer CEO Albert Bourla on CNN, Sweet recalled losing a speech competition while trying to raise money for college.
AlphaSense nearly doubles valuation to $7.5 billion in new funding round
AlphaSense nearly doubles valuation to $7.5 billion in new funding round June 3 : Market intelligence platform AlphaSense said on Wednesday it has raised $350 million at a valuation of $7.5 billion, nearly double that of its funding round two years ago. The round was led by Vitruvian Partners, Accenture Ventures, and J.P. Morgan Asset Management, with new investors including D. E. Shaw Ventures and Pinegrove Opportunity Partners. The funding highlights strong investor demand for AI-related...
Market research firm AlphaSense nearly doubles valuation to $7.5 billion in new funding round
Market research firm AlphaSense nearly doubles valuation to $7.5 billion in new funding round June 3 : Market intelligence platform AlphaSense said on Wednesday it has raised $350 million at a valuation of $7.5 billion, nearly double that of its previous funding round. The round was led by Vitruvian Partners, Accenture Ventures, and J.P. Morgan Asset Management, with new investors including D. E. Shaw Ventures and Pinegrove Opportunity Partners. Founded in 2011, AlphaSense is an AI-powered...
EU watchdog says von der Leyen should have kept Macron’s Mercosur text message
The EU’s transparency watchdog has accused the Commission of maladministration for failing to keep a text message from French President Emmanuel Macron to Ursula von der Leyen, the head of the EU executive, urging a freeze in talks on a major trade deal with Latin America. Macron’s text message in early 2024, exclusively reported by POLITICO, sought to halt talks on the trade accord with the Mercosur bloc within sight of the finish line. The deal was only approved at the beginning of this...
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
The highly anticipated SpaceX mega-IPO is part of a space frenzy that is moving beyond satellite connectivity, launch vehicles, and aerospace defense to the pharmaceutical sector. A growing number of companies are heading to lower Earth orbit to make medicines in microgravity. The range of commercial opportunities is expanding as foundational aerospace industries set the necessary infrastructure.
What is Blockchain: Everything You Need to Know (2022)
If you want to pay online, you need to register an account and provide credit card information. If you don't have a credit card, you can pay with bank transfer. With the rise of cryptocurrencies, these methods may become old.